Zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) - The Phase 3 ALPINE Trial

 SLIDE KIT   13   07/2021

ALPINE is a global, randomized phase 3 study comparing zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

In an interim analysis zanubrutinib was shown to have a superior response rate and a lower rate of atrial fibrillation/flutter as compared with ibrutinib. These data support that more selective BTK inhibition results in improved efficacy and safety outcomes.

Rating

Rate this resource